Compass Therapeutics, Inc. - CMPX STOCK NEWS

Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014, Compass focuses on developing proprietary antibody-based therapeutics to treat a variety of human diseases, with a strong emphasis on oncology.

The company’s core mission is to thoroughly address the tumor-immune synapse by utilizing combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass industrializes antibody discovery and decentralizes biologic validation through a partnership-first mentality, leveraging best-in-class technologies and top-tier academic laboratories globally. All novel scientific insights are validated extensively within Compass's own labs before proceeding to proprietary combination therapeutics aimed at human clinical trials.

In 2015, Compass secured a $120 million Series A financing to support its ambitious plans to build a fully-integrated biopharmaceutical company. The company’s robust pipeline includes three primary product candidates—CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody combining DLL4 and VEGF-A inhibitors, CTX-471 is a CD137 agonist, and CTX-8371 is a PD-1 x PD-L1 bispecific antibody. These candidates are in various stages of clinical development, targeting key pathways in angiogenesis, immune response activation, and immunosuppressive mechanisms within the tumor microenvironment.

Recently, Compass has achieved significant milestones. The company reported top-line data showing promising results in its Phase 2 COMPANION-003 trial and Phase 2/3 COMPANION-002 trial. Additionally, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for metastatic or locally advanced biliary tract cancer. Compass continues to make strides in advancing its product candidates through both standalone therapies and combinations with its proprietary pipeline antibodies.

Financially, Compass maintains a strong position, with a year-end 2023 cash balance of $152 million, extending its cash runway into mid-2026. The company’s net loss for 2023 was $42.5 million, showing a slight increase from the previous year, reflecting its intensified clinical and manufacturing activities.

Looking forward, Compass plans to continue its clinical trials and explore additional therapeutic areas. Key leadership changes and additions, such as the appointment of Vered Bisker-Leib, PhD, as CEO, reflect the company’s commitment to steering towards innovation and growth.

For more detailed and updated information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.